BSc MSc MPH
Clinical Trials Development Lead
I joined SITU in November 2018 as the Clinical Trials Development Lead. The purpose of my role is to establish and develop a portfolio of collaborative researchers, leading to the successful submission and set-up of surgical intervention trials. I’m responsible for identifying and discerning viable research proposals, and leading the development of these ideas into successful grant applications, engaging with new investigators and the SITU core team. I am the main point of contact in SITU for investigators who wish to develop new trials.
I graduated from the University of Nottingham in 2010 with a BSc (hons) in Mathematics, a Masters in Medical Statistics (MSc) from the University of Southampton in 2011 and a Masters of Public Health (MPH) from the University of Manchester in 2018. I previously worked as a medical statistician at the NHMRC Clinical Trials Centre at the University of Sydney where I was involved in teaching on a number of courses related to trial design and methodology including the MSc in Biostatistics and MSc in Clinical Trial Methodology. Prior to joining SITU I worked in the Nuffield Department of Population Health at the University of Oxford on meta-analyses of breast cancer trials. I have been involved in the design, conduct, analysis and reporting of a number of large randomised controlled trials and have a particular interest in the methodology and development of surgical trials.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2019), Lancet, 393, 1440 - 1452
Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis.
Philippou Y. et al, (2018), BJU Int
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Friedlander M. et al, (2018), Lancet Oncol, 19, 1126 - 1134